Diligence memo · auto-generated · as of July 2, 2026

CHINA BAICAOTANG MEDICINE Ltd

CHINA BAICAOTANG MEDICINE Ltd looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

CHINA BAICAOTANG MEDICINE Ltd operates in Pharmaceuticals, based in LIUZHOU CITY, GUANGXI PROVINCE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

CHINA BAICAOTANG MEDICINE Ltd has raised $15M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $8.9M on 2009-12-30.

Most recent recorded round closed around 2009-12-30.

Valuation (modeled)modeled

Provath models CHINA BAICAOTANG MEDICINE Ltd at approximately $277M (range $10M–$1.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.01× the median modeled value of Series A Pharmaceuticals companies in 2007–2009 (18 peers) — value vs value, same stage and era. Within the normal band (101% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 16.5 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.4× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 62% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 73% of those peers.

Closest niche peers: Sinocom Pharmaceutical, Inc., Vitae Pharmaceuticals, Inc, QUATRX PHARMACEUTICALS Co, Qrxpharma Ltd, Elixir Pharmaceuticals, Inc..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.